# OnCo record c-trak-tn (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/c-trak-tn/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "c-trak-tn", "NCT03145961" ;
  schema:name "c-TRAK TN"@en ;
  schema:alternateName "c-TRAK-TN"@en, "cTRAK TN"@en ;
  schema:description "c-TRAK TN, run from the Royal Marsden and the Institute of Cancer Research, was the first trial to use blood tests for tumour DNA to trigger treatment in triple-negative breast cancer. A quarter of patients tested positive within a year, but most of them already had visible metastases on scans, so the test came too late to prevent relapse with pembrolizumab."@en ;
  schema:url <https://onco.cc/trials/c-trak-tn/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03145961>, <https://doi.org/10.1016/j.annonc.2022.11.005> ;
  onco:status "completed" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/cruk/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/tnbc-residual-disease-decision/> ;
  onco:trials <https://onco.cc/trials/bre12-158/>, <https://onco.cc/trials/keynote-522/> .